All Content Outsourced Pharma

31. Hovione And Firstgene Announce Strategic Collaboration To Advance Virus-Like Particle Platform For Liver Cancer 5/6/2025

    Hovione, an international integrated pharmaceutical development and manufacturing organization, and Firstgene Life Sciences, a portfolio company of the Swiss incubator Xlife Sciences AG today announced a strategic collaboration to advance Hovione’s proprietary virus-like particle drug delivery platform for the targeted treatment of Hepatocellular Carcinoma (HCC), a therapeutic indication developed by Firstgene.

32. Microbix's Clot-Buster Drug Project Advances 5/5/2025

    Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, announces that its funding and commercialization partner, Sequel Pharma, LLC (“Sequel”), has executed an agreement with a leading international contract development and manufacturing organization (“CDMO”) for production of the formulated and packaged drug (i.e., “Drug Product”) of Kinlytic® urokinase (“Kinlytic”), a biologic drug for dissolving blood clots.

33. Roquette Announces A New Organization Following The Acquisition Of IFF Pharma Solutions 5/5/2025

    Roquette, a global leader in plant-based ingredients and pharmaceutical excipients for the health and nutrition sectors, announces today a new organization following the successful acquisition of IFF Pharma Solutions announced on May 1.

34. Aptar CSP Technologies Expands Service Offerings With Launch Of cGMP Early-Stage Clinical Manufacturing Site For Tablet And Capsule-Based Drug Products 5/5/2025

    Aptar CSP Technologies, part of AptarGroup, Inc. and a global leader in active material science solutions, announced the expansion of its service offerings with the launch of a cGMP-compliant manufacturing facility in New Jersey.

35. The Expanding Role Of CMC In Biotech Investor Decision-Making 5/5/2025

    With increasingly complex modalities, undruggable targets, rare diseases, and narrowly defined patient subpopulations, CMC is an important area of due diligence scrutiny for prospective investors and licensees. Part 1 of a two-part analysis.

36. Scorpius Holdings Announces Corporate Update Including Cost Optimization Initiatives, Strategic Corporate Developments, And Potential Opportunities For Expansion Into Southeast Asia 5/4/2025

    Scorpius Holdings, Inc (OTC: SCPX) (“Scorpius” or “the Company”), an integrated contract development and manufacturing organization ("CDMO”), today provided a corporate update highlighting key strategic initiatives, including cost optimization measures expected to yield over $6 million in annualized savings and the Company’s exploration of opportunities to expand operations into Southeast Asia through a potential biomanufacturing presence in Malaysia.

37. Comprehensive, Integrated BioServices 5/2/2025

    Discover more about optimized storage, packing, labeling, and global distribution, seamlessly integrated for your supply chain. Simplify complexity and enhance the reliability of your supply chain.

38. The Secret To True GMP-ness In The Cell & Gene Therapy Sector 5/2/2025

    Much of what we do in cell & gene therapy manufacturing is deeply habit-based. When employees understand the purpose behind a task, it supports their autonomy and competence.

39. AustinPX Site Tour 5/2/2025

    Take a virtual tour of AustinPx to explore advanced facilities, including KinetiSol™ technology, and discover how we enable scalable, sustainable performance.

40. 8 Ways To Drive Resilience In Oncology Drug Supply Chains 5/2/2025

    From traditional chemotherapy to advanced immunotherapies and nanotechnology, pharma/biotech companies must overcome logistical hurdles that affect their oncology products' availability and quality.